logo

NMTC

NeuroOne Medical·NASDAQ
--
--(--)
--
--(--)
0.75 / 10
Underperform

Fundamental breakdown reveals challenging profile (0.8/10). Supportive elements: Asset-MV and Cash-MV, although drawbacks are visible in Revenue-MV and Net income-Revenue. This suggests selective positioning.

Fundamental(0.75)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-1.36
Score0/3
Weight47.71%
1M Return-3.84%
ROA (%)
Value-44.63
Score3/3
Weight-15.54%
1M Return1.03%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight21.86%
1M Return-1.71%
Net income-Revenue
Value-0.17
Score1/3
Weight30.86%
1M Return-2.55%
Cash-UP
Value-0.06
Score2/3
Weight53.29%
1M Return-4.86%
Annualized net profit margin on total assets (%)
Value-44.63
Score3/3
Weight-15.54%
1M Return1.03%
Interest coverage ratio (EBIT / Interest expense) (%)
Value42.48
Score2/3
Weight24.65%
1M Return-1.95%
Asset-MV
Value-0.50
Score2/3
Weight-25.64%
1M Return1.60%
Cash-MV
Value-0.07
Score2/3
Weight-55.06%
1M Return3.31%
Net profit / Total profit (%)
Value100.00
Score1/3
Weight33.43%
1M Return-2.89%
Is NMTC fundamentally strong?
  • NMTC scores 0.75/10 on fundamentals and holds a Premium valuation at present. Backed by its -91.34% ROE, -39.63% net margin, -10.91 P/E ratio, 5.56 P/B ratio, and 80.43% earnings growth, these metrics solidify its Underperform investment rating.